INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2016

Inulin-propionate ester (IPE-27) significantly reduced ad libitum energy intake compared with inulin control and IPE-54 in a crossover trial.

Researchers developed inulin short-chain fatty acid esters to deliver propionate directly to the colon and tested them in vitro and in humans. In a randomized controlled crossover study, participants received 10 g/day of IPE-27, IPE-54, or inulin control for 7 days. In vivo, IPE-27 produced greater 13C recovery in breath CO2 than IPE-54 (64.9 vs. 24.9%, P = 0.001) and reduced energy intake during an ad libitum test meal compared with inulin (439.5 vs. 703.9 kcal, P = 0.025) and IPE-54 (439.5 vs. 659.3 kcal, P = 0.025). Intake with IPE-54 did not differ significantly from inulin control.

Study type
Randomized controlled crossover study and in vitro fermentations
Who was studied
Human participants (sample size not specified)
What was measured
Ad libitum food intake (kcal) and 13C recovery in breath CO2

THE PAPER

Randomised clinical study: inulin short-chain fatty acid esters for targeted delivery of short-chain fatty acids to the human colon.

Polyviou T, MacDougall K, Chambers ES, Viardot A, Psichas A, Jawaid S, Harris HC, Edwards CA, Simpson L, Murphy KG, Zac-Varghese SE, Blundell JE, Dhillo WS, Bloom SR, Frost GS, Preston T, Tedford MC, Morrison DJ. Aliment Pharmacol Ther, 2016.

PubMed 27464984 ↗DOI 10.1111/apt.13749 ↗

Gut & microbiomeNutrients & adequacyWeight & appetite

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.